The specter of generic rivalry has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the future of connected medicinal portfolios. While initial times saw impressive returns, the exclusivity expiration has allowed the door for cheaper substitutes, likely reducing profitability and creating a real